People with stroke history who receive clot-busting therapy fare better

November 16, 2011

ST. PAUL, Minn. - People with a history of stroke or diabetes who were given clot-busting drugs to break up blood clots after stroke fared better than those who did not receive the drugs, according to a study published in the November 16, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology.

"The use of these drugs, called thrombolytic therapy, can limit damage and disability due to blood clots," said study author Kennedy R. Lees, MD, of the University of Glasgow in Scotland. "However, current guidelines can keep people from receiving the therapy if they have a history of stroke and diabetes."

For the study, scientists gathered data from 23,062 people who received clot-busting therapy along with 6,166 people who did not receive clot-busting therapy. Measurements of how well people were able to function 90 days after the stroke were taken from both groups. A total of 19 percent of the people had diabetes and 17 percent had a prior stroke.

Stroke outcomes were measured on a scale of zero to six using the modified Rankin Scale. Zero represented no symptoms, three represented moderate disability meaning a person requires some help but is able to walk unassisted and a six indicated death.

The study found that 43 percent of people with diabetes who received the clot-busting therapy had a disability score of two or less, compared with only 34 percent of diabetes patients who did not receive the therapy. Additionally, the study found 48 percent of patients with previous stroke who received clot-busting therapy scored a two or less, compared with 35 percent of patients with previous stroke who did not receive the therapy.

"Better outcomes with therapy show that people with prior stroke or diabetes should not be excluded from receiving thrombolytic therapy," said Lees.
-end-
The study was supported by the Virtual International Stroke Trials Archive (VISTA), the University of Glasgow and the European Stroke Organization. VISTA is a not for profit collaboration of clinical scientists that aims to make clinical trial data available for further research.

The American Academy of Neurology, an association of more than 24,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as epilepsy, dystonia, migraine, Huntington's disease, and dementia.

For more information about the American Academy of Neurology, visit http://www.aan.com.

VIDEO:
http://www.youtube.com/AANChannel

TEXT:
http://www.aan.com/press

TWEETS:
http://www.twitter.com/AANPublic

American Academy of Neurology

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.